AlphAIAlphAI — Financial news for AI agents
BenzingaJUL 282 min read$COHN

Cohen & Company Sets Release Date for Second Quarter 2025 Financial Results - Cohen & Co (AMEX:COHN)

PHILADELPHIA and NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Cohen & Company Inc. COHN will release its financial results for the second quarter 2025 on Thursday, July 31, 2025. The Company will host a conference call at 10:00 a.m. Eastern Time ( ET ) that day to discuss these results.

Original reporting
Benzinga · Globe Newswire
Published Jul 28, 2025, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$COHN
Neutral
medium confidence
Mentioned
$COHN
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$COHNNeutralMed
01

Why it matters

The scheduled release could lead to increased trading volume and volatility around July 31, 2025, depending on the results and market expectations.

02

Market read

The event is primarily relevant to traders and investors holding or considering positions in COHN, with limited broader market impact.

03

What to watch

Market-wide macroeconomic conditions or sector trends could overshadow company-specific news, affecting stock performance regardless of earnings.

Relevance 6/10Timing: high

Background

Cohen & Company Inc. is a financial services firm scheduled to announce its Q2 2025 financial results, which can influence short-term trading activity.

Company-level read

Ticker impact

$COHNNeutralMedium confidence
Context

The upcoming financial results release is a scheduled event that can influence short-term trading activity.

Expected impact

Potential for increased volatility; possible short-term upward or downward movement depending on results and market expectations.

Evidence & confidence

Scheduled earnings releases typically influence stock price volatility; however, without prior earnings data or analyst expectations, the direction is uncertain.

Market effects

Sector

Limited sector impact; the release pertains specifically to Cohen & Company Inc., a financial services firm, with no immediate sector-wide implications.

Regional

Minimal regional impact; the event is company-specific and scheduled in the U.S. markets.

Global

Negligible global relevance; primarily of interest to investors and traders focused on the company's stock.

Counterpoint

What could challenge this read

The earnings release may be a non-event if results meet market expectations, leading to minimal price movement.

Key entities

  • Company
    Cohen & Company Inc.

    A financial services firm listed on the AMEX.

Read at source← All news

Related articles

AUG 3
$COHNMed

COHEN & COMPANY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Cohen & Co Inc. (COHN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 COHEN & COMPANY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Board Declares Quarterly Dividend of $0.25 per Share Revenue of $69.5 Million Net Income Attributable to Cohen & Company Inc. of $3.6 Million, or $0.94 per Diluted Share Adjusted Pre-Tax Income of $10.1 Mi

SEC EDGAR 8-K6 min
JUN 26
$COHNMedAI 8/10

2026 - 06 - 26 | Elroy Air to Become Publicly Traded Company via Business Combination with Inflection Point - led SPAC | NDAQ: CMII

Elroy Air will become a publicly traded company through a business combination with SPAC Columbus Circle Capital Corp II (Nasdaq: CMII), led by Inflection Point Asset Management. The deal values Elroy Air at about $800M pre-money and ~$1.0B enterprise value, with $165M+ committed PIPE capital. Closing is expected in Q4 2026. Elroy’s Chaparral VTOL drone targets 500+ lbs cargo; demand pipeline exceeds 1,400 aircraft and $5B potential revenue.

stockhouse.com6 min
OCT 23
$BMYMed

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.

rttnews.com2 min